Clinical Trial Update: A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years [Phase 3]

View source ↗

Summary

A Phase 3 study of Janssen's Ad26.RSV.preF-based RSV vaccine regimen in adults aged 60-75 has completed and posted its results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF-based vaccine (Ad26.RSV.preF)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Respiratory Syncytial Virus Prevention | Phase 3 | Status: COMPLETED | Results posted: 2023-09-06